Which has higher earnings and valuation, FARN or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£11.52 N/A ImmuPharma N/A N/A -£2.51M -£0.83 N/A

Does the media favor FARN or IMM?

In the previous week, Faron Pharmaceuticals Oy had 4 more articles in the media than ImmuPharma. MarketBeat recorded 5 mentions for Faron Pharmaceuticals Oy and 1 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.67 beat Faron Pharmaceuticals Oy's score of 0.38 indicating that ImmuPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Faron Pharmaceuticals Oy 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is REDX or IMM more profitable?

ImmuPharma has a net margin of 3,519.56% compared to Redx Pharma's net margin of 0.00%. Redx Pharma's return on equity of -180.80% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets Redx Pharma N/A -180.80% -43.95% ImmuPharma 3,519.56% -559.87% -43.00%

Does the media prefer REDX or IMM?

In the previous week, Redx Pharma and Redx Pharma both had 1 articles in the media. ImmuPharma's average media sentiment score of 0.67 beat Redx Pharma's score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redx Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, POLB or IMM?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Poolbeg Pharma N/A N/A -£4.50B -£0.79 N/A ImmuPharma N/A N/A -£2.51M -£0.83 N/A

Does the media favor POLB or IMM?

In the previous week, Poolbeg Pharma had 2 more articles in the media than ImmuPharma. MarketBeat recorded 3 mentions for Poolbeg Pharma and 1 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.67 beat Poolbeg Pharma's score of -0.08 indicating that ImmuPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ImmuPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMM or ETX more profitable?

ImmuPharma has a net margin of 3,519.56% compared to e-therapeutics' net margin of 0.00%. e-therapeutics' return on equity of -38.75% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets ImmuPharma 3,519.56% -559.87% -43.00% e-therapeutics N/A -38.75% -29.10%

Which has better valuation and earnings, IMM or HEMO?

ImmuPharma is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.83 N/A Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A

Does the media prefer IMM or HEMO?

In the previous week, ImmuPharma and ImmuPharma both had 1 articles in the media. ImmuPharma's average media sentiment score of 0.67 beat Hemogenyx Pharmaceuticals' score of 0.37 indicating that ImmuPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemogenyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ImmuPharma (IMM) Competitors

GBX 3.80 +0.52 (+15.88%)

As of 03:56 AM Eastern

Compare

IMM vs. FARN, REDX, POLB, ETX, and HEMO

Should you buy ImmuPharma stock or one of its competitors? ImmuPharma's main competitors and comparable companies include Faron Pharmaceuticals Oy (FARN), Redx Pharma (REDX), Poolbeg Pharma (POLB), e-therapeutics (ETX), and Hemogenyx Pharmaceuticals (HEMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

In the previous week, Faron Pharmaceuticals Oy had 4 more articles in the media than ImmuPharma. MarketBeat recorded 5 mentions for Faron Pharmaceuticals Oy and 1 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.67 beat Faron Pharmaceuticals Oy's score of 0.38 indicating that ImmuPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%
ImmuPharma	3,519.56%	-559.87%	-43.00%

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 6.2% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy has a beta of 1.116, meaning that its share price is 12% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, meaning that its share price is 201% more volatile than the broader market.

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Redx Pharma?

Redx Pharma (LON:REDX) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

ImmuPharma has lower revenue, but higher earnings than Redx Pharma. ImmuPharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A

In the previous week, Redx Pharma and Redx Pharma both had 1 articles in the media. ImmuPharma's average media sentiment score of 0.67 beat Redx Pharma's score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redx Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Redx Pharma has a beta of -0.53, suggesting that its stock price is 153% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, suggesting that its stock price is 201% more volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to Redx Pharma's net margin of 0.00%. Redx Pharma's return on equity of -180.80% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redx Pharma	N/A	-180.80%	-43.95%
ImmuPharma	3,519.56%	-559.87%	-43.00%

Summary

ImmuPharma beats Redx Pharma on 6 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A

5.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 2 more articles in the media than ImmuPharma. MarketBeat recorded 3 mentions for Poolbeg Pharma and 1 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.67 beat Poolbeg Pharma's score of -0.08 indicating that ImmuPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmuPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuPharma has a net margin of 3,519.56% compared to Poolbeg Pharma's net margin of 0.00%. Poolbeg Pharma's return on equity of -71.28% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-71.28%	-21.33%
ImmuPharma	3,519.56%	-559.87%	-43.00%

Poolbeg Pharma has a beta of 1.828, suggesting that its share price is 83% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, suggesting that its share price is 201% more volatile than the broader market.

Summary

ImmuPharma beats Poolbeg Pharma on 6 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to e-therapeutics?

ImmuPharma (LON:IMM) and e-therapeutics (LON:ETX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

ImmuPharma has higher earnings, but lower revenue than e-therapeutics. ImmuPharma is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A

In the previous week, ImmuPharma had 1 more articles in the media than e-therapeutics. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for e-therapeutics. ImmuPharma's average media sentiment score of 0.67 beat e-therapeutics' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuPharma	Positive
e-therapeutics	Neutral

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to e-therapeutics' net margin of 0.00%. e-therapeutics' return on equity of -38.75% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-559.87%	-43.00%
e-therapeutics	N/A	-38.75%	-29.10%

ImmuPharma has a beta of 3.014, suggesting that its share price is 201% more volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Summary

ImmuPharma and e-therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does ImmuPharma compare to Hemogenyx Pharmaceuticals?

ImmuPharma (LON:IMM) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

ImmuPharma is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

ImmuPharma has a net margin of 3,519.56% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Hemogenyx Pharmaceuticals' return on equity of -409.57% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-559.87%	-43.00%
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%

ImmuPharma has a beta of 3.014, indicating that its stock price is 201% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its stock price is 49% more volatile than the broader market.

In the previous week, ImmuPharma and ImmuPharma both had 1 articles in the media. ImmuPharma's average media sentiment score of 0.67 beat Hemogenyx Pharmaceuticals' score of 0.37 indicating that ImmuPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemogenyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 6.2% of ImmuPharma shares are held by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ImmuPharma and Hemogenyx Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMM vs. The Competition

Export

Metric	ImmuPharma	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£23.68M	£3.85B	£7.14B	£2.84B
Dividend Yield	0.77%	3.65%	2.53%	6.26%
P/E Ratio	-4.57	12.99	274.34	366.82
Price / Sales	N/A	1,293.73	614.18	89,165.41
Price / Cash	20.50	39.04	27.22	27.89
Price / Book	5.88	17.34	11.34	7.08
Net Income	-£2.51M	-£23.20M	£3.49B	£5.89B
7 Day Performance	16.59%	-2.11%	-1.27%	-0.49%
1 Month Performance	5.42%	-10.19%	-5.94%	-0.99%
1 Year Performance	-65.81%	17.45%	7.29%	23.00%

ImmuPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMM ImmuPharma	N/A	GBX 3.80 +15.9%	N/A	-72.5%	£23.68M	N/A	N/A	13
FARN Faron Pharmaceuticals Oy	N/A	GBX 35.30 -3.3%	N/A	-80.4%	£71.62M	N/A	N/A	34	News Coverage Gap Up
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
POLB Poolbeg Pharma	N/A	GBX 7.18 -2.3%	N/A	+100.1%	£54.82M	N/A	N/A	12	Earnings Report Gap Down
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IMM) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuPharma (IMM) Competitors

IMM vs. FARN, REDX, POLB, ETX, and HEMO

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Summary

How does ImmuPharma compare to Redx Pharma?

Summary

How does ImmuPharma compare to Poolbeg Pharma?

Summary

How does ImmuPharma compare to e-therapeutics?

Summary

How does ImmuPharma compare to Hemogenyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuPharma (IMM) Competitors

IMM vs. FARN, REDX, POLB, ETX, and HEMO

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Does the media favor FARN or IMM?

Is FARN or IMM more profitable?

Which has higher earnings and valuation, FARN or IMM?

Do insiders & institutionals have more ownership in FARN or IMM?

Which has more risk and volatility, FARN or IMM?

Summary

How does ImmuPharma compare to Redx Pharma?

Which has stronger earnings and valuation, REDX or IMM?

Does the media prefer REDX or IMM?

Do institutionals and insiders hold more shares of REDX or IMM?

Which has more volatility & risk, REDX or IMM?

Is REDX or IMM more profitable?

Summary

How does ImmuPharma compare to Poolbeg Pharma?

Which has preferable earnings & valuation, POLB or IMM?

Do institutionals and insiders believe in POLB or IMM?

Does the media favor POLB or IMM?

Is POLB or IMM more profitable?

Which has more risk & volatility, POLB or IMM?

Summary

How does ImmuPharma compare to e-therapeutics?

Which has preferable valuation and earnings, IMM or ETX?

Does the media refer more to IMM or ETX?

Do insiders and institutionals hold more shares of IMM or ETX?

Is IMM or ETX more profitable?

Which has more risk and volatility, IMM or ETX?

Summary

How does ImmuPharma compare to Hemogenyx Pharmaceuticals?

Which has better valuation and earnings, IMM or HEMO?

Is IMM or HEMO more profitable?

Which has more risk & volatility, IMM or HEMO?

Does the media prefer IMM or HEMO?

Do insiders and institutionals believe in IMM or HEMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools